REMAP-CAP’S NEW TRIAL DEVELOPMENTS
The world of REMAP-CAP is constantly evolving, here’s what’s new!
REMAP-CAP, a groundbreaking trial that has most recently been primarily focused on finding treatments for COVID-19, has now been selected by the National Institute for Healthcare and Research to evaluate therapeutic interventions for influenza.
REMAP-CAP: NEW RESULTS FROM THE ACE2 RAS DOMAIN!
New results have recently been published from the ACE2 RAS domain, one of the multiple therapeutic domains within REMAP-CAP, a trial within Spiral’s manifest of studies.
SNAP Trial Celebrates One Year!
We have another important milestone to celebrate! On the 17th of February 2023, the SNAP (Staphylococcus Aureus Network Adaptive Platform) Trial reached its one-year anniversary.
Better Health Outcomes Together - The PANORAMIC Case Study with Lead Statistician Ly-Mee Yu
Spiral talks with Ly-Mee Yu, Lead Statistician of the PANORAMIC Trial on the devastating effects of the pandemic and how trials like PANORAMIC, with the help of Spiral’s software, are aiming to provide better health outcomes for those affected by the virus.
ASCOT Trial Results are in!
New results are in for the ASCOT Trial (Australasian Covid-19 Trial), another study in Spiral’s manifest of platform trials. This platform trial was set up to evaluate 3 different treatment approaches for effectiveness against COVID-19. Each of these approaches is called a 'domain'. The findings from the anticoagulation domain have recently been published in the New England Journal of Medicine Evidence.
ACTA Insights with Audrey
After two years of online meetings, attending the Australian Clinical Trials Alliance Annual Science meeting in Adelaide in November felt fantastic. It was a whirlwind of activity, new technology, connections, learning, and, importantly, an excellent opportunity to connect with industry peers.
Case Study - SNAP Trial with Professor Steven Tong
As clinical trials in the world grow and develop, so too do the opportunities for Spiral to make a difference with our savvy platform software.
We speak to Professor Steven Tong about the SNAP Trial, his experience working with the team at Spiral, and the application and impact of our Spinnaker software in his study.
Meet Anna - Spiral’s Office Manager and Data Coordinator
At Spiral, we’re always working hard to better meet the needs of our clients and partners. As our product evolves so too does our team. Meet Anna Williams, the newest full-time member of the Spiral whānau (family). Our office manager and data coordinator.
Oxford Insights
The Bodleian Library is the main research library of the University of Oxford. It's one of the oldest libraries in Europe and is stacked with books dating back 600 years. Spiral’s CEO and Founder, Audrey Shearer found her recent visit here, while meeting clients for the Panoramic trial, a thought-provoking one.
Case Study—TAME Study with Dr Glenn Eastwood.
Spinnaker Case Study—We speak with Dr Glenn Eastwood, TAME Chief Principal Investigator, about the TAME Trial study and how Spiral has enabled them to produce a database they can be confident in.
Thousands more patients gain access to second ground-breaking antiviral via Panoramic
A new anti-viral, Paxlovid, has recently been added to the PANORAMIC national study in the UK.
REMAP-CAP: New Results for Antiplatelets in Critical COVID-19
The efficacy of antiplatelet therapy in critically ill patients with COVID-19 has always been uncertain. However recent findings have shown that it’s unlikely that adding an antiplatelet agent to anticoagulation will increase the number of organ support-free days in critically ill patients with COVID-19. Although it’s possible that survival in the first 90 days can be improved, according to the results of the REMAP-CAP trial.